Company news
Oncolytics Biotech Inc. news in 2017
Oncolytics Biotech Inc.'s news releases, calls and decks from 2017, newest first.
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
December 27, 2017
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer
December 5, 2017
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit
December 4, 2017
Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer
November 30, 2017
Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
November 16, 2017
Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results
November 8, 2017
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors
November 2, 2017
Oncolytics Biotech® to Present at the 2017 BIO Investor Forum
October 11, 2017
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
September 19, 2017
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
September 18, 2017
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
September 14, 2017
Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
September 11, 2017
Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results
August 3, 2017
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
August 1, 2017
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
July 26, 2017
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
June 29, 2017
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego
June 27, 2017
Oncolytics Biotech® Announces Closing of Public Offering of Units
June 1, 2017
Oncolytics Biotech® Prices Public Offering of Units
May 24, 2017
Oncolytics Biotech® Announces Proposed Public Offering
May 23, 2017
Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
May 23, 2017
Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
May 17, 2017
Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
May 8, 2017
Oncolytics Biotech® Inc. Announces 2017 First Quarter Results
May 5, 2017
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders
May 4, 2017
Oncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders
April 27, 2017
Oncolytics Biotech® Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference
April 26, 2017
Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan
April 12, 2017
Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer
April 5, 2017
Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer
March 31, 2017
Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma
March 16, 2017
Oncolytics Biotech® Inc. Announces 2016 Year-End Results
March 10, 2017
Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting
March 2, 2017
Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO
January 19, 2017